SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).

@article{Petrylak2004SWOG9R,
  title={SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA).},
  author={Daniel Peter Petrylak and Catherine M. Tangen and Maha H A Hussain and Primo N. Lara and J. Owen Jones and M E Talpin and Patrick A. Burch and Graham F. Greene and Eric Jay Small and E. David Crawford},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3}
}
3 Background: The median survival of AIPCA patients (pts) treated with M+P is 10-12 months. Phase I/II trials of AIPCA pts treated with D+E reported survivals of 20-23 months. SWOG 99-16 was designed to compare the survival D+E to M+P. METHODS 770 men with progressive AIPCA were randomized to either Arm 1) Dexamethasone 60 mg premedication; D=60 mg/m2 day… CONTINUE READING